Aridis Pharmaceuticals Licenses AstraZeneca’s late-stage monoclonal antibody, survatoxumab

By Neha Madhwani

Pharma Deals Review: Vol 2021 Issue 8 (Table of Contents)

Published: 16 Aug-2021

DOI: 10.3833/pdr.v2021.i8.2632     ISSN: 1756-7874

Section: Licensing



In a bid to bolster its pneumonia franchise, Aridis has entered into a worldwide license agreement with AstraZeneca to in-license the late-stage monoclonal antibody candidate, suvratoxumab, a Phase III ready asset...

This page is available to subscribers only.

Not a subscriber? Join here

Why should I subscribe?

Already Registered? Please login using the top left purple box.

Copyright: © IQVIA 2018

IQVIA™ Pharma Deals: PharmaDeals Review: Article Details